

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Carcinogenicity (Inhalation) : Category 2
Specific target organ toxicity : Category 2 (Liver, Testis)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H351 Suspected of causing cancer if inhaled.
H373 May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical attention.
Storage:
P405 Store locked up.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version 9.2 Revision Date: 08/07/2025 SDS Number: 76204-00030 Date of last issue: 04/14/2025
Date of first issue: 03/17/2015

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data available	9004-34-6	$\geq 5 - < 10$ *
Grazoprevir	No data available	1350462-55-3	$\geq 5 - < 10$ *
Elbasvir	No data available	1370468-36-2	$\geq 1 - < 5$ *
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0	$\geq 1 - < 5$ *
Titanium dioxide	Titanic anhydride	13463-67-7	$\geq 0.1 - < 1$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Suspected of causing cancer if inhaled.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Chlorine compounds
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version 9.2 Revision Date: 08/07/2025 SDS Number: 76204-00030 Date of last issue: 04/14/2025
Date of first issue: 03/17/2015

released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Grazoprevir	1350462-55-3	TWA	260 µg/m ³ (OEB 2)	Internal
Elbasvir	1370468-36-	TWA	150 µg/m ³ (OEB	Internal

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version 9.2 Revision Date: 08/07/2025 SDS Number: 76204-00030 Date of last issue: 04/14/2025
Date of first issue: 03/17/2015

	2		2)	
Magnesium stearate	557-04-0	TWA	10 mg/m ³	CA AB OEL
		TWA (Inhalable)	10 mg/m ³	CA BC OEL
		TWA (Respirable)	3 mg/m ³	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m ³	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m ³	CA QC OEL
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Color	: white
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: Not applicable
Relative vapor density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Grazoprevir:

Result : No skin irritation

Elbasvir:

Species : reconstructed human epidermis (RhE)
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Grazoprevir:

Species	:	Bovine cornea
Result	:	No eye irritation

Elbasvir:

Species	:	Bovine cornea
Result	:	No eye irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Titanium dioxide:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Grazoprevir:

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Dermal
Result	:	Not a skin sensitizer.

Elbasvir:

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Dermal
Species	:	Mouse
Result	:	negative

Magnesium stearate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Rat

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Titanium dioxide:

Species : Rat
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : positive
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Grazoprevir:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: negative

Test Type: Multi-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: No effects on fertility., No effects on fetal development.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
Result: No effects on fetal development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
Result: No effects on fetal development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous
Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight
Result: No effects on fetal development.

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Components:

Grazoprevir:

Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Grazoprevir:

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 30 Days
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 180 Days
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 15 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 270 Days
Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse
NOAEL : 200 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Liver, Kidney, Blood

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Blood, Testis

Species : Monkey
NOAEL : 10 mg/kg
Exposure time : 8 Days
Remarks : No significant adverse effects were reported

Elbasvir:

Species : Rat
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Titanium dioxide:

Species	:	Rat
NOAEL	:	24,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	28 Days

Species	:	Rat
NOAEL	:	10 mg/m ³
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion	:	Symptoms: Headache, Gastrointestinal disturbance
-----------	---	--

Elbasvir:

Ingestion	:	Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion
-----------	---	---

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish	:	LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Grazoprevir:

Toxicity to fish	:	LC50 (<i>Cyprinodon variegatus</i> (sheepshead minnow)): > 10 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility.
------------------	---	--

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): > 10 mg/l Exposure time: 48 h
---	---	---

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 8.9 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

LC50 (Menidia beryllina (Silverside)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 7.7 mg/l

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

		Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility. NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.84 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 271.9 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Magnesium stearate:		
Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Bioaccumulative potential

Components:

Grazoprevir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

Elbasvir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Grazoprevir:

Distribution among environmental compartments : log Koc: 4.01

Elbasvir:

Distribution among environmental compartments : log Koc: 5.24

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

(Elbasvir)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Elbasvir)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Elbasvir)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Elbasvir)

Class : 9
Packing group : III
Labels : 9
ERG Code : 171
Marine pollutant : yes(Elbasvir)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
9.2	08/07/2025	76204-00030	Date of first issue: 03/17/2015

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 08/07/2025
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8